InsiderTrades

Form 4 for ACRS Aclaris Therapeutics, Inc.

Accepted 2022-06-06 00:00:00 ET · period of report 2022-06-02 · accession 0001209191-22-034585 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-06-06 2022-06-03 ACRS Humphries William D. Dir M - OptEx — +3,356 19.6K +21% —
DM 2022-06-06 2022-06-02 ACRS Humphries William D. Dir A - Grant $0.00 +20.3K 15.8K New $0
D 2022-06-06 2022-06-03 ACRS Humphries William D. Dir M - OptEx $0.00 -3,356 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-06-03 M A 3,356 — 19,565 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
2 Derivative Restricted Stock Units 2022-06-02 A A 4,507 $0.00 4,507 D — · — to — 4,507 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F2) This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. (F4) The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date.
3 Derivative Restricted Stock Units 2022-06-03 M D 3,356 $0.00 0 D — · — to — 3,356 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F5) The shares underlying these restricted stock units vested on June 3, 2022.
4 Derivative Stock Option (Right to Buy) 2022-06-02 A A 15,750 $0.00 15,750 D $14.48 · — to 2032-06-01 15,750 Common Stock (F3) The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. (F2) This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy.